Recent Gene Therapy News
On August 20, 2020 Audentes Therapeutics, which was taken over by Astellas (ALPMY) for over $3 billion, announced that a third patient has passed away in a clinical trial evaluating its gene therapy product AT132 for the treatment of the life-threatening neuromuscular X-linked Myotubular Myopathy (XLMTM).
The neuromuscular disease is . . .
This content is for paid subscribers.
Trick or Trade
August 25, 2020
